Flexion Therapeutics Inc (NASDAQ:FLXN) shares were up 5.5% on Thursday . The company traded as high as $19.21 and last traded at $19.06. Approximately 920,700 shares changed hands during trading, an increase of 53% from the average daily volume of 601,575 shares. The stock had previously closed at $18.07.

A number of research analysts have recently weighed in on FLXN shares. ValuEngine raised shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. Benchmark started coverage on shares of Flexion Therapeutics in a research report on Thursday, June 28th. They set a “buy” rating and a $39.00 target price for the company. BidaskClub raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 14th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $91.50.

The firm has a market capitalization of $680.30 million, a P/E ratio of -4.61 and a beta of 0.71. The company has a current ratio of 12.90, a quick ratio of 12.78 and a debt-to-equity ratio of 0.80.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.06. The business had revenue of $3.80 million during the quarter, compared to the consensus estimate of $3.96 million. equities analysts predict that Flexion Therapeutics Inc will post -4.75 EPS for the current year.

In other Flexion Therapeutics news, CEO Michael D. Clayman acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 9th. The stock was bought at an average cost of $22.33 per share, with a total value of $223,300.00. Following the acquisition, the chief executive officer now owns 75,282 shares in the company, valued at $1,681,047.06. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Neil Bodick sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $25.07, for a total transaction of $1,253,500.00. The disclosure for this sale can be found here. 14.59% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alps Advisors Inc. boosted its holdings in Flexion Therapeutics by 8.5% in the 2nd quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after buying an additional 4,272 shares during the period. Ardsley Advisory Partners boosted its holdings in Flexion Therapeutics by 14.4% in the 2nd quarter. Ardsley Advisory Partners now owns 595,000 shares of the specialty pharmaceutical company’s stock worth $15,381,000 after buying an additional 75,000 shares during the period. Clearline Capital LP bought a new position in Flexion Therapeutics in the 2nd quarter worth approximately $5,411,000. Mutual of America Capital Management LLC bought a new position in Flexion Therapeutics in the 2nd quarter worth approximately $1,250,000. Finally, Gagnon Securities LLC boosted its holdings in Flexion Therapeutics by 18.4% in the 2nd quarter. Gagnon Securities LLC now owns 390,791 shares of the specialty pharmaceutical company’s stock worth $10,102,000 after buying an additional 60,796 shares during the period. 99.09% of the stock is owned by institutional investors.

Flexion Therapeutics Company Profile (NASDAQ:FLXN)

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

See Also: How to Invest in Growth Stocks

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.